½ÃÀ庸°í¼­
»óǰÄÚµå
1529590

In Vivo CRO ½ÃÀå : ºÐÀÚ À¯Çüº°, Ä¡·á ºÐ¾ßº°, ¼­ºñ½º À¯Çüº°, Áö¿ªº°

In Vivo CRO Market, By Type of Molecule, By Therapeutic Area, By Service Type, By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è In Vivo CRO ½ÃÀåÀº 2024³â 47¾ï ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2024-2031³â CAGR 8.5%·Î 2031³â¿¡´Â 83¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º¸°í¼­ ¹üÀ§ º¸°í¼­ »ó¼¼
±âÁØ ¿¬µµ 2023³â 2024³â ½ÃÀå ±Ô¸ð 47¾ï ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2019-2023³â ¿¹Ãø ±â°£ 2024-2031³â
¿¹Ãø ±â°£ 2024-2031³â CAGR 8.50% 2031³â ±Ý¾× Àü¸Á 83¾ï 1,000¸¸ ´Þ·¯
±×¸². In Vivo CRO ½ÃÀå Á¡À¯À²(%), Áö¿ªº°, 2024³â
In Vivo CRO Market-IMG1

In Vivo CRO ½ÃÀå¿¡´Â ºñÀÓ»ó ¶Ç´Â ÀüÀÓ»ó ´Ü°è¿¡ ÀÖ´Â Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷À» Áö¿øÇÏ´Â À§Å¹¿¬±¸±â°ü(CRO)ÀÌ Æ÷ÇԵǸç, À̵é Àü¹®¾÷ü¿¡ ¿¬±¸ ¼ö¿ä¸¦ ¾Æ¿ô¼Ò½ÌÇÏ¿© »ì¾ÆÀÖ´Â µ¿¹°À» ÀÌ¿ëÇÑ ½ÇÇè ¹× ½ÃÇèÀ» ÅëÇØ ½Å¾à Èĺ¸¹°ÁúÀÇ À¯È¿¼º, µ¶¼º, ¾ÈÀü¼º Æò°¡¸¦ Áö¿øÇÕ´Ï´Ù. À̸¦ ÅëÇØ ÀǾàǰ °³¹ßÀÚÀÇ ¸®½ºÅ©¸¦ ÁÙÀ̰í ÀǾàǰ ½ÂÀÎ ÀýÂ÷¸¦ °¡¼ÓÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀǾàǰ ¹× ÀÇ·á ±â¼ú Çõ½Å¿¡ ´ëÇÑ R&D ºñ¿ë Áõ°¡´Â ¼¼°è In Vivo CRO ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀÔ´Ï´Ù. ±×·¯³ª ¾ö°ÝÇÑ µ¿¹°º¹Áö ±ÔÁ¦¿Í ´ëü ½ÃÇè¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ½ÃÀå ¼ºÀåÀÇ °É¸²µ¹·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

¼¼°è In Vivo CRO ½ÃÀåÀº ÀǾàǰ R&D ºñ¿ë Áõ°¡, Áúº´ Ä¡·áÀÇ ¹ßÀü, ÀǾàǰ °³¹ß ±â°£ ¹× ºñ¿ë Àý°¨¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ±×·¯³ª µ¿¹° ½ÇÇè¿¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦¿Í Àå±â ¿ÂĨ ¹× ü¿Ü ½ÃÇè°ú °°Àº ´ëü ½ÃÇè¹ý¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡´Â ½ÃÀåÀ» ¾ïÁ¦ÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. COVID-19 »çÅ·ΠÀÎÇØ CRO°¡ Ä¡·áÁ¦¸¦ ¹ß°ßÇϰí ÀüÀÓ»ó ¿¬±¸¿¡¼­ Á¦¾àȸ»ç¸¦ Áö¿øÇØ¾ß ÇÒ Çʿ伺ÀÌ ºÎ°¢µÇ¸é¼­, CRO°¡ µ¿¹°½ÇÇèÀ» ´ëüÇÒ ¼ö ÀÖ´Â »õ·Î¿î Å×½ºÆ® ¼Ö·ç¼ÇÀ» Á¦°øÇØ¾ß ÇÒ Çʿ伺ÀÌ ´õ¿í ºÎ°¢µÇ°í ÀÖ½À´Ï´Ù. Çʿ伺ÀÌ ºÎ°¢µÇ¾ú½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • ÀÌ º¸°í¼­´Â 2023³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2024-2031³â)ÀÇ ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯)¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)¿¡ ´ëÇØ »ó¼¼È÷ ºÐ¼®ÇÏ¿© ¼¼°è In Vivo CRO ½ÃÀå¿¡ ´ëÇØ Á¶»çÇß½À´Ï´Ù.
  • ¶ÇÇÑ, ´Ù¾çÇÑ ºÎ¹®ÀÇ ÀáÀçÀû ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.
  • ÀÌ º¸°í¼­´Â ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ¼º°ú ¹× Àü·«°ú °°Àº ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ¼¼°è In Vivo CRO ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.
  • ÀÌ º¸°í¼­ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ­, ½ÃÀå È®´ë ¹× ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
  • In Vivo CRO ¼¼°è ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ÁøÀÔÀÚ, À繫 ºÐ¼®°¡ µî ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è In Vivo CRO ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ½±°Ô ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú °¡Á¤

  • Á¶»ç ¸ñÀû
  • °¡Á¤
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • º¸°í¼­ ¼³¸í
    • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à
  • Coherent Opportunity Map(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
  • ¿µÇ⠺м®
  • ½ÃÀå µ¿Çâ
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • Àμö¿Í Á¦ÈÞ ½Ã³ª¸®¿À
  • ÀÚ±Ý Á¶´Þ°ú ÅõÀÚ
  • PEST ºÐ¼®
  • Porters ºÐ¼®

Á¦4Àå ¼¼°èÀÇ In Vivo CRO ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

  • ÀüüÀûÀÎ ¿µÇâ
  • Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê
  • COVID-19ÀÇ ½ÃÀå¿¡ ´ëÇÑ ¿µÇâ

Á¦5Àå ¼¼°èÀÇ In Vivo CRO ½ÃÀå, ºÐÀÚ À¯Çüº°, 2019-2031³â(10¾ï ´Þ·¯)

  • ¼Ò°³
  • ¼ÒºÐÀÚ
  • °Å´ë ºÐÀÚ

Á¦6Àå ¼¼°èÀÇ In Vivo CRO ½ÃÀå, Ä¡·á ºÐ¾ßº°, 2019-2031³â(10¾ï ´Þ·¯)

  • ¼Ò°³
  • Á¾¾çÇÐ
  • ´ç´¢º´
  • ÀÚ°¡¸é¿ªÁúȯ/¿°Áõ¼º Áúȯ
  • °¨¿°Áõ
  • ÁßÃ߽Űæ°è Áõ»ó
  • ±âŸ

Á¦7Àå ¼¼°èÀÇ In Vivo CRO ½ÃÀå, ¼­ºñ½º À¯Çüº°, 2019-2031³â(10¾ï ´Þ·¯)

  • ¼Ò°³
  • ÀüÀÓ»ó½ÃÇè
  • ÀÓ»ó Á¶»ç ¼­ºñ½º
  • ½ÇÇè½Ç ¼­ºñ½º
  • ÄÁ¼³ÆÃ ¼­ºñ½º
  • ±âŸ

Á¦8Àå ¼¼°èÀÇ In Vivo CRO ½ÃÀå, Áö¿ªº°, 2019-2031³â(10¾ï ´Þ·¯)

  • ¼Ò°³
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿

Á¦9Àå °æÀï »óȲ

  • ±â¾÷ °³¿ä
    • IQVIA Inc.
    • Crown Bioscience
    • Taconic Biosciences, Inc.
    • PsychoGenics Inc.
    • Evotec
    • Janvier Labs
    • Biocytogen Boston Corp
    • GemPharmatech
    • Charles River Laboratories
    • Icon Plc
    • Labcorp Drug Development
    • Parexel International Corporation
    • SMO Clinical Research(I) Pvt Ltd.
    • WuXi AppTec
    • ICON plc
    • Syneos Health

Á¦10Àå ¾Ö³Î¸®½ºÆ®ÀÇ Ãßõ»çÇ×

  • Wheel of Fortune
  • Coherent Opportunity Map

Á¦11Àå Âü°í¹®Çå°ú Á¶»ç ¹æ¹ý

  • Âü°í¹®Çå
  • Á¶»ç ¹æ¹ý
ksm 24.08.23

The global in vivo CRO market is estimated to be valued at USD 4.70 Bn in 2024 and is expected to reach USD 8.31 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 8.5% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2024: US$ 4.70 Bn
Historical Data for: 2019 To 2023 Forecast Period: 2024 to 2031
Forecast Period 2024 to 2031 CAGR: 8.50% 2031 Value Projection: US$ 8.31 Bn
Figure. In Vivo CRO Market Share (%), By Region 2024
In Vivo CRO Market - IMG1

In vivo CRO market involves contract research organizations (CROs) that help pharmaceutical and biotechnology companies in non-clinical or pre-clinical stages of drug development by outsourcing their research needs to these specialized firms. CROs conduct experiments and tests on live animals and help evaluate the efficacy, toxicity, and safety of new drug candidates. This reduces risks for drug developers and accelerates the drug approval process. Rising R&D expenditure on pharmaceuticals and medical innovations is a key driver for growth of the global in vivo CRO market. However, factors such as stringent animal welfare regulations and increasing demand for alternative testing methods pose challenges for the market.

Market Dynamics

The global in vivo CRO market is driven by rising pharmaceutical R&D expenditure, advancements in disease treatment, and growing need to reduce drug development timelines and costs. However, stringent regulations for animal testing and rising preference for alternative testing methods, such as organ-on-chip and in vitro testing, act as restraints for the market. Development of human-on-chip technology provides an opportunity for companies in this market to offer novel alternative testing solutions and align with industry shift toward non-animal methods. The COVID-19 outbreak highlighted the need for CROs to find treatments and help drug makers in pre-clinical research, thereby presenting lucrative prospects for players in this market.

Key Features of the Study:

  • -This report provides in-depth analysis of the global in vivo CRO market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global in vivo CRO market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Charles River, Envigo, Taconic Biosciences, Jackson Laboratory, Crown Biosciences, Shanghai SLAC, Changle Rongshi, Pengxin Huasu and Syngene International.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global in vivo CRO market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global in vivo CRO market.

Detailed Segmentation-

  • By Type of Molecule
    • Small Molecules
    • Large Molecules
  • By Therapeutic Area
    • Oncology
    • Cardiology
    • Diabetes
    • Autoimmune/Inflammation Conditions
    • Infectious Diseases
    • CNS Conditions
    • Others
  • By Service Type
    • Preclinical Testing
    • Clinical Research Services
    • Laboratory Services
    • Consulting Services
  • Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • IQVIA Inc.
    • Crown Bioscience
    • Taconic Biosciences, Inc.
    • PsychoGenics Inc.
    • Evotec
    • Janvier Labs
    • Biocytogen Boston Corp
    • GemPharmatech
    • Charles River Laboratories
    • Icon Plc
    • Labcorp Drug Development
    • Parexel International Corporation
    • SMO Clinical Research (I) Pvt Ltd.
    • WuXi AppTec
    • ICON plc
    • Syneos Health

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Type of Molecule
    • Market Snapshot, By Therapeutic Area
    • Market Snapshot, By Service Type
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Regulatory Scenario
  • Acquisitions and Partnerships Scenario
  • Funding and Investments
  • PEST Analysis
  • Porter's Analysis

4. Global In Vivo CRO Market - Impact of Coronavirus (COVID-19) Pandemic

  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the Market

5. Global In Vivo CRO Market, By Type of Molecule, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Small Molecules
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Large Molecules
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global In Vivo CRO Market, By Therapeutic Area, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Oncology
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Diabetes
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Autoimmune/Inflammation Conditions
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Infectious Disease
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • CNS Conditions
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global In Vivo CRO Market, By Service Type, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Preclinical Testing
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Clinical Research Services
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Laboratory Services
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Consulting Services
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global In Vivo CRO Market, By Region, 2019 - 2031, (USD Bn)

  • Introduction
    • Market Share Analysis, By Region, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, For Region, 2020-2031
    • Regional Trends
      • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type of Molecule, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Area, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type of Molecule, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Area, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type of Molecule, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Area, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type of Molecule, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Area, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type of Molecule, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Area, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • GCC
      • Israel
      • Rest of Middle East
      • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type of Molecule, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Area, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
      • North Africa
      • Central Africa
      • South Africa

9. Competitive Landscape

  • Company Profiles
    • IQVIA Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Crown Bioscience
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Taconic Biosciences, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • PsychoGenics Inc.
    • Evotec
    • Janvier Labs
    • Biocytogen Boston Corp
    • GemPharmatech
    • Charles River Laboratories
    • Icon Plc
    • Labcorp Drug Development
    • Parexel International Corporation
    • SMO Clinical Research (I) Pvt Ltd.
    • WuXi AppTec
    • ICON plc
    • Syneos Health

10. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

11. References and Research Methodology

  • References
  • Research Methodology
  • About Us and Sales Contact
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦